Latest official price of ensifentrine - Ohtuvayre market in 2025

Ensifentine inhalation suspension (Ensifentrine) is an innovative drug that has attracted much attention in the international respiratory field in recent years. Its trade name is Ohtuvayre. As the first inhaled drug with dual inhibitory activity of both PDE3 and PDE4 , it provides a new treatment idea for chronic airway diseases such as chronic obstructive pulmonary disease (COPD). The research and development logic of this drug is based on improving the bronchodilation effect while also having anti-inflammatory properties. It has a multi-dimensional effect in improving respiratory ventilation, relieving chronic cough and asthma, and reducing the risk of exacerbation. Therefore, it is regarded by international guidelines as one of the breakthrough innovative therapies.

Although Exefantine has received high attention around the world, it has not yet been officially launched in China, and it is not currently included in the medical insurance catalog. In some administrative regions, there is news that the drug may have completed marketing registration, but the actual supply needs to be confirmed with local medical institutions. However, since it has not yet been included in the mainland supply system, its price, reimbursement ratio and hospital procurement channels are still at a stage of opaque information.

According to overseas official market information, the specification of the US version of the original Ohtuvayre is 3mg/2.5mL ( 60 doses per box), and a single box is priced at more than 40,000 yuan. The higher price is mainly due to its innovative mechanism, new drug research and development costs, and production requirements for special dosage forms of inhaled suspension solutions. Due to limited global supply channels and exchange rate fluctuations, its domestic acquisition costs tend to fluctuate with market changes. It is worth noting that there is currently no imitation version on the market, and there is no regionally authorized version, so the market price temporarily lacks competitive pressure.

Overall, exefantine, as an innovative inhaled drug that is expected to change the treatment landscape of COPD , is currently on the market overseas but cannot be purchased domestically. It is expensive, not included in medical insurance, and there are no generic versions. As real-world data continues to accumulate, its future domestic listing and price policy direction deserve continued attention.

Reference materials: https://www.drugs.com/monograph/ensifentrine.html